Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor for Advanced Tumor Angiogenesis Research

Principle Overview: The Power of Multi-Target Tyrosine Kinase Inhibition

Anlotinib hydrochloride is a potent, small-molecule multi-target tyrosine kinase inhibitor (TKI) developed to address the complex signaling environment of tumor angiogenesis. Unlike traditional, single-target inhibitors, Anlotinib simultaneously inhibits VEGFR2, PDGFRβ, and FGFR1—three critical receptors involved in pathological blood vessel formation. This broad-spectrum inhibition disrupts the tyrosine kinase signaling pathway, leading to pronounced endothelial cell migration inhibition, suppression of capillary-like tube formation, and downstream ERK signaling pathway inhibition (Lin et al., 2018).

APExBIO supplies Anlotinib (hydrochloride) (CAS 1058157-76-8) as a rigorously validated research reagent, enabling cancer researchers to dissect the mechanisms of tumor angiogenesis inhibition and benchmark novel anti-angiogenic strategies.

Experimental Workflow: Step-by-Step Protocols and Enhancements

1. Preparation and Storage

• Stock Solution: Dissolve Anlotinib hydrochloride in DMSO to prepare a 10 mM stock solution. Store aliquots at -20°C, protected from light.
• Working Concentrations: For in vitro assays, typical concentrations range from 1–100 nM. Notably, Anlotinib exhibits IC₅₀ values of 5.6 ± 1.2 nM (VEGFR2), 8.7 ± 3.4 nM (PDGFRβ), and 11.7 ± 4.1 nM (FGFR1), allowing for precise dose-response studies.

2. Cellular Assays for Anti-Angiogenic Activity

• Cell Line Selection: Human vascular endothelial cells (e.g., EA.hy 926) are the gold standard for angiogenesis research.
• Key Assays:
  • Wound Healing (Scratch) Assay: Quantifies endothelial cell migration inhibition upon VEGF, PDGF-BB, or FGF-2 stimulation and Anlotinib treatment.
  • Capillary Tube Formation Assay: Visualizes and measures the ability of endothelial cells to form capillary-like structures in response to pro-angiogenic factors, with Anlotinib added to assess capillary tube formation inhibition.
  • Transwell Migration Assay: Provides quantitative metrics on cell migration across a membrane, directly linking migration dynamics to Anlotinib exposure.

Protocol Tip: For optimal results, pre-incubate endothelial cells with Anlotinib for 30–60 minutes before adding growth factors. This ensures rapid target engagement and enhances assay sensitivity.

3. In Vivo and Ex Vivo Angiogenesis Models

• Rat Aortic Ring Assay: Demonstrates ex vivo vessel sprouting. Anlotinib significantly reduces microvessel outgrowth in a concentration-dependent fashion.
• Chicken Chorioallantoic Membrane (CAM) Assay: Used to visualize neovascularization. Anlotinib application results in a marked decrease in microvessel density compared to controls and other clinically used agents (Lin et al., 2018).

Advanced Applications and Comparative Advantages

1. Outperforming Legacy TKIs in Cancer Research

Compared to established angiogenesis inhibitors like sunitinib, sorafenib, and nintedanib, Anlotinib hydrochloride offers superior inhibition of VEGFR2, PDGFRβ, and FGFR1. This translates to stronger blockade of both endothelial cell migration and tube formation at lower concentrations, as shown by head-to-head experiments (Lin et al., 2018).

Researchers seeking a comprehensive tool for tumor angiogenesis inhibition will benefit from Anlotinib’s high membrane permeability, rapid cellular uptake, and robust pharmacokinetic profile—including high tissue accumulation (notably in tumor, lung, liver, kidney, and heart) and the ability to cross the blood-brain barrier.

2. Mechanistic and Translational Insights

Anlotinib’s role as a VEGFR2 PDGFRβ FGFR1 inhibitor makes it invaluable for dissecting the interplay between pro-angiogenic cytokines and downstream signaling. Inhibition of the ERK pathway is reproducibly observed in treated endothelial cells, linking receptor blockade to functional outcomes. These features are particularly relevant for translational oncology models and drug combination studies.

For an in-depth exploration of Anlotinib’s systems pharmacology and translational relevance, see the article "Anlotinib Hydrochloride: Systems Pharmacology and Translational Applications", which complements this protocol by offering tissue-specific insights and advanced modeling strategies.

3. Integration into Multi-Modal Research Pipelines

Given its broad kinase inhibition and favorable safety profile (LD₅₀ of 1735.9 mg/kg with minimal systemic toxicity), Anlotinib is well-suited for combination studies with immunotherapies or cytotoxic agents. Its ability to inhibit multiple angiogenic pathways positions it as a versatile scaffold for exploring resistance mechanisms and synergistic anti-cancer effects.

This integrative approach aligns with perspectives presented in "Anlotinib Hydrochloride: Redefining Multi-Target Angiogenesis Inhibition", where Anlotinib’s unique multi-kinase profile is contrasted with legacy TKIs and its role in shaping next-generation translational workflows is highlighted.

Troubleshooting and Optimization Tips

• Assay Sensitivity: If migration or tube formation inhibition appears modest, verify stock solution integrity (DMSO quality, storage at -20°C). Prepare fresh working solutions for each experiment.
• Concentration Titration: Always include a dose-response series; optimal effects are typically observed at 5–20 nM for most in vitro models but may require adjustment depending on cell line sensitivity.
• Serum Interference: High serum concentrations can mask anti-angiogenic effects. Use reduced-serum (0.5–2% FBS) conditions for migration and tube formation assays.
• Endpoint Quantification: Employ automated image analysis tools (e.g., ImageJ, AngioTool) for unbiased quantification of migration distance and tube network complexity.
• Phosphorylation Readouts: When probing ERK or receptor phosphorylation, harvest cells rapidly (within 5–15 min of stimulation) to capture transient signaling events.
• Comparative Controls: Include sunitinib, sorafenib, or nintedanib as reference standards to benchmark Anlotinib’s efficacy in your specific system, as recommended in "Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor".

Future Outlook: Expanding the Frontiers of Tumor Angiogenesis Inhibition

Anlotinib hydrochloride exemplifies the evolution of anti-angiogenic small molecules—offering unmatched efficacy in the inhibition of key receptor kinases and downstream pathways driving tumor vascularization. As research pivots toward overcoming resistance and enhancing therapeutic durability, Anlotinib’s multi-target profile will be central to the development of next-generation combination regimens and personalized cancer models.

Further integration into high-content screening, 3D microvascular models, and patient-derived xenograft (PDX) systems will unlock new mechanistic insights and translational opportunities. The synergy between APExBIO’s validated compound supply and robust preclinical data ensures that researchers can confidently advance their studies from bench to bedside.

For a broader vision on how Anlotinib is redefining angiogenesis research, "Redefining Tumor Angiogenesis Inhibition: Mechanistic and Translational Advances" extends this discussion by highlighting emerging translational strategies and case studies demonstrating real-world impact.

Conclusion

Anlotinib (hydrochloride) from APExBIO empowers researchers with a scientifically validated, multi-target approach to tumor angiogenesis inhibition. With its nanomolar potency, superior selectivity, and proven translational relevance, Anlotinib is an indispensable tool for advancing the frontiers of cancer research and tyrosine kinase signaling pathway analysis.